AstraZeneca and Daiichi's HER2 ADC hits goal in pivotal trial
Fierce Biotech,
AstraZeneca and Daiichi Sankyo’s HER2-targeting antibody drug conjugate (ADC) has hit the primary endpoint in a pivotal phase 2…
AstraZeneca and Daiichi Sankyo’s HER2-targeting antibody drug conjugate (ADC) has hit the primary endpoint in a pivotal phase 2…
(Nasdaq:SGEN) today announced that results of a phase 1b clinical trial of tucatinib in combination with standard of care…
Jul 9, 2018 The American Society of Clinical Oncology (ASCO) released an update to its guidelines on the optimal management of…